Randomized Adjuvant Chemotherapy of EGFR-Mutated Non-Small Cell Lung Cancer Patients with or without Icotinib Consolidation Therapy.

Randomized Adjuvant Chemotherapy of EGFR-Mutated Non-Small Cell Lung Cancer Patients with or without Icotinib Consolidation Therapy.

Epidermal growth factor receptor (EGFR) mutations occur in up to 50% of Asian patients with non-small cell lung cancer (NSCLC). Treatment of advanced NSCLC patients with EGFR-tyrosine kinase inhibitor (EGFR-TKI) confers a significant survival benefit. This study assessed the efficacy and safety of c...

Full description

Bibliographic Details
Main Authors:	Siyang Feng, Yuanyuan Wang, Kaican Cai, Hua Wu, Gang Xiong, Haofei Wang, Ziliang Zhang
Format:	Article
Language:	English
Published:	Public Library of Science (PLoS) 2015-01-01
Series:	PLoS ONE
Online Access:	http://europepmc.org/articles/PMC4608803?pdf=render

Similar Items

Outcomes of concurrent versus sequential icotinib therapy and chemotherapy in advanced non‐small cell lung cancer with sensitive EGFR mutations
by: Yun Zhang, et al.
Published: (2021-05-01)

Clinical Analysis of Icotinib on Beneficiary of  Advanced Non-small Cell Lung Cancer with EGFR Common Mutation
by: Xiaowen JIANG, et al.
Published: (2016-04-01)

Icotinib is as efficacious as gefitinib for brain metastasis of EGFR mutated non-small-cell lung cancer
by: Kejun Liu, et al.
Published: (2020-01-01)

Icotinib as Adjuvant Treatment for Stage II-IIIA Lung Adenocarcinoma Patients with EGFR Mutation (ICWIP Study): Study Protocol for a Randomised Controlled Trial
by: Liu YT, et al.
Published: (2020-06-01)

Icotinib versus Cisplatin Plus Docetaxel as Adjuvant Chemotherapy in Patients with Stage II (N1+) Non-Small Cell Lung Cancer Harboring Positive EGFR Mutations: A Single-Center Retrospective Study
by: Pan S, et al.
Published: (2021-02-01)

The effect of icotinib combined with chemotherapy in untreated non-small-cell lung cancer that harbored EGFR-sensitive mutations in a real-life setting: a retrospective analysis
by: Wang LL, et al.
Published: (2018-04-01)

Effective treatment with icotinib in lung adenocarcinoma with EGFR and ALK co-alterations and brain metastasis
by: Ye CY, et al.
Published: (2016-10-01)

Efficacy of Icotinib for Advanced Non-small Cell Lung Cancer Patients with EGFR Status Identified
by: Yiping ZHANG, et al.
Published: (2013-03-01)

Network meta-analysis of erlotinib, gefitinib, afatinib and icotinib in patients with advanced non-small-cell lung cancer harboring EGFR mutations.
by: Wenhua Liang, et al.
Published: (2014-01-01)

The Prognostic Value of Baseline Distant Metastasis in Icotinib-Treated Patients with EGFR-Mutated Stage IV Non-Small Cell Lung Cancer
by: Wang L, et al.
Published: (2021-03-01)

Positive response to Icotinib in metastatic lung adenocarcinoma with acquiring EGFR Leu792H mutation after AZD9291 treatment: a case report
by: Junhui Wang, et al.
Published: (2019-02-01)

Clinical Observation of Icotinib Hydrochloride for Advanced Non-small Cell Lung Cancer Patients with EGFR Status Identified
by: Xi LI, et al.
Published: (2015-12-01)

Real‐world efficacy and potential mechanism of resistance of icotinib in Asian advanced non‐small cell lung cancer with EGFR uncommon mutations: A multi‐center study
by: Lei Lei, et al.
Published: (2020-01-01)

The Impact of Sequence of Chemotherapy and EGFR-TKI Treatment on Different EGFR Mutation Lung Adenocarcinoma
by: Fu-Tsai Chung, et al.
Published: (2015-01-01)

Efficacy of icotinib in advanced lung squamous cell carcinoma
by: Shuai Liang, et al.
Published: (2018-09-01)

Combination of icotinib, surgery, and internal-radiotherapy of a patient with lung cancer severely metastasized to the vertebrae bones with EGFR mutation: a case report
by: Qu LL, et al.
Published: (2015-06-01)

Icotinib versus docetaxel used in lung adenocarcinoma patients who failed platinum-based chemotherapy: a retrospective study
by: He W, et al.
Published: (2016-07-01)

Icotinib alone or with bevacizumab as first‐line therapy in Chinese patients with advanced nonsquamous non‐small cell lung cancer and activating EGFR mutations: A retrospective study
by: Zhansheng Jiang, et al.
Published: (2021-09-01)

Comparison of the Efficacy and Safety of Icotinib with Standard Second-line  Chemotherapy in Previously Treated Advanced Non-small Cell Lung Cancer
by: Shuyang YAO, et al.
Published: (2015-06-01)

Efficacy of Chemotherapy after EGFR-TKIs Resistance in 191 Patients with Unknow EGFR Gene Mutation in Advanced Lung Adenocarcinoma
by: Ping HE, et al.
Published: (2013-10-01)

Combination of EGFR-TKIs with chemotherapy versus chemotherapy or EGFR-TKIs alone in advanced NSCLC patients with EGFR mutation
by: Wen M, et al.
Published: (2018-11-01)

An active treatment of lung adenocarcinoma cancer with brain metastases: icotinib
by: Zhang Y, et al.
Published: (2015-06-01)

Apatinib plus icotinib in treating advanced non-small cell lung cancer after icotinib treatment failure: a retrospective study
by: Xu J, et al.
Published: (2017-10-01)

Sequence-dependent synergistic cytotoxicity of icotinib and pemetrexed in human lung cancer cell lines in vitro and in vivo
by: Tianze Liu, et al.
Published: (2019-04-01)

Meta-analysis of postoperative adjuvant chemotherapy without radiotherapy in early stage non-small cell lung cancer
by: Chen YY, et al.
Published: (2015-08-01)

Ubiquitin Ligase Cbl-b Is Involved in Icotinib (BPI-2009H)-Induced Apoptosis and G1 Phase Arrest of EGFR Mutation-Positive Non-Small-Cell Lung Cancer
by: Xiaodong Mu, et al.
Published: (2013-01-01)

Alterations in EGFR and related genes following neo-adjuvant chemotherapy in Chinese patients with non-small cell lung cancer.
by: Shuhang Wang, et al.
Published: (2013-01-01)

Resistance to Both Chemotherapy and EGFR-TKI in Small Cell Lung Cancer With EGFR 19-Del Mutation: A Case Report
by: Lingfei Wang, et al.
Published: (2020-07-01)

Efficacy and safety of icotinib in patients with brain metastases from lung adenocarcinoma
by: Xu J, et al.
Published: (2016-05-01)

Efficacy of EGFR-TKI Plus Chemotherapy or Monotherapy as First-Line Treatment for Advanced EGFR-Mutant Lung Adenocarcinoma Patients With Co-Mutations
by: Zhengyu Yang, et al.
Published: (2021-08-01)

Effect of EGFR-TKI on Lymphangiogenesis of Lung Cancer with EGFR Mutation
by: Minghui CAI, et al.
Published: (2014-12-01)

Icotinib inhibits the proliferation of hepatocellular carcinoma cells in vitro and in vivo dependently on EGFR activation and PDL1 expression
by: Sun J, et al.
Published: (2018-11-01)

Icotinib hydrochloride enhances chemo- and radiosensitivity by inhibiting EGFR signaling and attenuating RAD51 expression and function in Hela S3 cells
by: Wang X, et al.
Published: (2018-03-01)

Icotinib is an active treatment of non-small-cell lung cancer: a retrospective study.
by: Xiaofeng Chen, et al.
Published: (2014-01-01)

EGFR T790M mutation after chemotherapy for small cell lung cancer transformation of EGFR-positive non-small cell lung cancer
by: Tomoaki Sonoda, et al.
Published: (2018-01-01)

Efficacy of Icotinib Hydrochloride in the Treatment of Advanced Non-small Cell Lung Cancer
by: Xianglei Ma, et al.
Published: (2013-09-01)

Efficacy and safety of icotinib in patients with brain metastases from lung adenocarcinoma [Corrigendum]
by: Xu J, et al.
Published: (2017-03-01)

EGFR Mutations and Lung Cancer.
Published: (2005-11-01)

Adjuvant chemotherapy protocols for lung cancer
by: Sameer Shrirangwar, et al.
Published: (2018-01-01)

Anlotinib can overcome acquired resistance to EGFR‐TKIs via FGFR1 signaling in non‐small cell lung cancer without harboring EGFR T790M mutation
by: Zengzhi Lian, et al.
Published: (2020-07-01)